YS Biopharma Co Ltd
NASDAQ:LSB

Watchlist Manager
YS Biopharma Co Ltd Logo
YS Biopharma Co Ltd
NASDAQ:LSB
Watchlist
Price: 3.06 USD -8.66%
Market Cap: 58.4m USD
Have any thoughts about
YS Biopharma Co Ltd?
Write Note

Intrinsic Value

The intrinsic value of one LSB stock under the Base Case scenario is 3.48 USD. Compared to the current market price of 3.06 USD, YS Biopharma Co Ltd is Undervalued by 12%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LSB Intrinsic Value
3.48 USD
Undervaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
YS Biopharma Co Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LSB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LSB?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about YS Biopharma Co Ltd

Provide an overview of the primary business activities
of YS Biopharma Co Ltd.

What unique competitive advantages
does YS Biopharma Co Ltd hold over its rivals?

What risks and challenges
does YS Biopharma Co Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for YS Biopharma Co Ltd.

Provide P/S
for YS Biopharma Co Ltd.

Provide P/E
for YS Biopharma Co Ltd.

Provide P/OCF
for YS Biopharma Co Ltd.

Provide P/FCFE
for YS Biopharma Co Ltd.

Provide P/B
for YS Biopharma Co Ltd.

Provide EV/S
for YS Biopharma Co Ltd.

Provide EV/GP
for YS Biopharma Co Ltd.

Provide EV/EBITDA
for YS Biopharma Co Ltd.

Provide EV/EBIT
for YS Biopharma Co Ltd.

Provide EV/OCF
for YS Biopharma Co Ltd.

Provide EV/FCFF
for YS Biopharma Co Ltd.

Provide EV/IC
for YS Biopharma Co Ltd.

Show me price targets
for YS Biopharma Co Ltd made by professional analysts.

What are the Revenue projections
for YS Biopharma Co Ltd?

How accurate were the past Revenue estimates
for YS Biopharma Co Ltd?

What are the Net Income projections
for YS Biopharma Co Ltd?

How accurate were the past Net Income estimates
for YS Biopharma Co Ltd?

What are the EPS projections
for YS Biopharma Co Ltd?

How accurate were the past EPS estimates
for YS Biopharma Co Ltd?

What are the EBIT projections
for YS Biopharma Co Ltd?

How accurate were the past EBIT estimates
for YS Biopharma Co Ltd?

Compare the revenue forecasts
for YS Biopharma Co Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of YS Biopharma Co Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of YS Biopharma Co Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of YS Biopharma Co Ltd compared to its peers.

Compare the P/E ratios
of YS Biopharma Co Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing YS Biopharma Co Ltd with its peers.

Analyze the financial leverage
of YS Biopharma Co Ltd compared to its main competitors.

Show all profitability ratios
for YS Biopharma Co Ltd.

Provide ROE
for YS Biopharma Co Ltd.

Provide ROA
for YS Biopharma Co Ltd.

Provide ROIC
for YS Biopharma Co Ltd.

Provide ROCE
for YS Biopharma Co Ltd.

Provide Gross Margin
for YS Biopharma Co Ltd.

Provide Operating Margin
for YS Biopharma Co Ltd.

Provide Net Margin
for YS Biopharma Co Ltd.

Provide FCF Margin
for YS Biopharma Co Ltd.

Show all solvency ratios
for YS Biopharma Co Ltd.

Provide D/E Ratio
for YS Biopharma Co Ltd.

Provide D/A Ratio
for YS Biopharma Co Ltd.

Provide Interest Coverage Ratio
for YS Biopharma Co Ltd.

Provide Altman Z-Score Ratio
for YS Biopharma Co Ltd.

Provide Quick Ratio
for YS Biopharma Co Ltd.

Provide Current Ratio
for YS Biopharma Co Ltd.

Provide Cash Ratio
for YS Biopharma Co Ltd.

What is the historical Revenue growth
over the last 5 years for YS Biopharma Co Ltd?

What is the historical Net Income growth
over the last 5 years for YS Biopharma Co Ltd?

What is the current Free Cash Flow
of YS Biopharma Co Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for YS Biopharma Co Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
YS Biopharma Co Ltd

Balance Sheet Decomposition
YS Biopharma Co Ltd

Current Assets 903.2m
Cash & Short-Term Investments 246.4m
Receivables 444.2m
Other Current Assets 212.7m
Non-Current Assets 609.9m
PP&E 480.6m
Intangibles 71.2m
Other Non-Current Assets 58m
Current Liabilities 802.2m
Accounts Payable 67.8m
Accrued Liabilities 413.9m
Other Current Liabilities 320.6m
Non-Current Liabilities 125.6m
Long-Term Debt 99m
Other Non-Current Liabilities 26.6m
Efficiency

Earnings Waterfall
YS Biopharma Co Ltd

Revenue
573.4m CNY
Cost of Revenue
-117.7m CNY
Gross Profit
455.7m CNY
Operating Expenses
-744.1m CNY
Operating Income
-288.4m CNY
Other Expenses
-145m CNY
Net Income
-433.5m CNY

Free Cash Flow Analysis
YS Biopharma Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

LSB Profitability Score
Profitability Due Diligence

YS Biopharma Co Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
21/100
Profitability
Score

YS Biopharma Co Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

LSB Solvency Score
Solvency Due Diligence

YS Biopharma Co Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
40/100
Solvency
Score

YS Biopharma Co Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LSB Price Targets Summary
YS Biopharma Co Ltd

Wall Street analysts forecast LSB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LSB is 3.16 USD with a low forecast of 3.13 USD and a high forecast of 3.26 USD.

Lowest
Price Target
3.13 USD
2% Upside
Average
Price Target
3.16 USD
3% Upside
Highest
Price Target
3.26 USD
6% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LSB?

Click here to dive deeper.

Dividends

YS Biopharma Co Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for LSB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

YS Biopharma Co Ltd Logo
YS Biopharma Co Ltd

Country

China

Industry

Biotechnology

Market Cap

62m USD

Dividend Yield

0%

Description

YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Contact

BEIJING
Beijing
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District
+861089202086
www.ysbiopharm.com

IPO

-

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one LSB stock?

The intrinsic value of one LSB stock under the Base Case scenario is 3.48 USD.

Is LSB stock undervalued or overvalued?

Compared to the current market price of 3.06 USD, YS Biopharma Co Ltd is Undervalued by 12%.

Back to Top